Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.
Department of Pharmaceutical Biosciences, Pharmacometrics Research Group, Uppsala University, Uppsala, Sweden.
Diabetes Obes Metab. 2018 Mar;20(3):660-666. doi: 10.1111/dom.13138. Epub 2017 Dec 4.
To quantify the postprandial triglyceride (TG) response of chylomicrons and very-low-density lipoprotein-V6 (VLDL-V6) after a high-fat meal in lean, obese and very obese healthy individuals, using a mechanistic population lipokinetic modelling approach.
Healthy individuals from three body mass index population categories: lean (18.5-24.9 kg/m ), obese (30-33 kg/m ), and very obese (34-40 kg/m ) were enrolled in a clinical study to assess the TG response after a high-fat meal, containing 60% fat. Non-linear mixed-effect modelling was used to analyse the TG concentrations of chylomicrons and large VLDL-V6 particles.
The TGs in chylomicrons and VLDL-V6 particles had a prominent postprandial peak and represented the majority of the postprandial response; only the VLDL-V6 showed a difference across the populations. A turn-over model successfully described the TG concentration-time profiles of both chylomicrons and large VLDL-V6 particles after the high-fat meal. This model consisted of four compartments: two transit compartments for the lag between meal consumption and appearance of TGs in the blood, and one compartment each for the chylomicrons and large VLDL-V6 particles. The rate constants for the production of chylomicrons and elimination of large VLDL-V6 particles, along with the conversion rate of chylomicrons to large VLDL-V6 particles were well defined.
This is the first lipokinetic model to describe the absorption of TGs from dietary fats into the blood stream and compares the dynamics of TGs in chylomicrons and large VLDL-V6 particles among lean, obese and very obese people. Such a model can be used to identify where pharmacological therapies act, thereby improving the determination of efficacy, and identifying complementary mechanisms for combinational drug therapies.
使用基于机制的群体脂质动力学建模方法,量化瘦人、肥胖者和非常肥胖者健康个体在高脂餐后乳糜微粒和极低密度脂蛋白-V6(VLDL-V6)的餐后甘油三酯(TG)反应。
从三个体重指数人群类别中招募健康个体:瘦(18.5-24.9kg/m²)、肥胖(30-33kg/m²)和非常肥胖(34-40kg/m²),以评估高脂肪餐后的 TG 反应,该餐包含 60%的脂肪。使用非线性混合效应模型分析乳糜微粒和大 VLDL-V6 颗粒的 TG 浓度。
乳糜微粒和 VLDL-V6 颗粒中的 TG 具有明显的餐后高峰,代表了大部分的餐后反应;只有 VLDL-V6 在人群中存在差异。周转模型成功描述了高脂肪餐后乳糜微粒和大 VLDL-V6 颗粒的 TG 浓度时间曲线。该模型由四个隔室组成:两个用于餐食摄入和 TG 出现在血液之间延迟的转运隔室,以及一个用于乳糜微粒和大 VLDL-V6 颗粒的隔室。乳糜微粒和大 VLDL-V6 颗粒的生成速率常数以及乳糜微粒向大 VLDL-V6 颗粒的转化率得到了很好的定义。
这是第一个描述膳食脂肪中的 TG 从肠道吸收到血液中的脂质动力学模型,并比较了瘦人、肥胖者和非常肥胖者之间乳糜微粒和大 VLDL-V6 颗粒中 TG 的动力学。这样的模型可用于识别药理学疗法的作用部位,从而提高疗效的确定,并识别联合药物疗法的互补机制。